Spots Global Cancer Trial Database for Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Official Title: Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Study ID: NCT00100243
Conditions
Interventions
Study Description
Brief Summary: This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
San Diego Center for Urology, La Mesa, California, United States
Southwest Florida Urological Associates, Fort Myers, Florida, United States
Panama City Urological Center, Panama City, Florida, United States
Columbus Urology Research, LLC, Columbus, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
Urological Associates of Lancaster, Lancaster, Pennsylvania, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Contact Details
Name: Marc Garnick, MD
Affiliation: PRAECIS Pharmaceuticals Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
